Ex-Workers: LifeMD Providers Saw 25 Patients Per Hour
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk lists telehealth company LifeMD on its website as a provider offering "legitimate medicine sourcing and patient support" for people seeking GLP-1 drugs including Ozempic and Wegovy.
- Former LifeMD workers told STAT the company sought to maximize the volume of prescriptions it issued at the expense of patient safety, pressing providers to work at a pace they described as not clinically responsible.
- LifeMD providers were sometimes expected to review the cases of 25 people per hour based solely on electronic forms the patients filled out — the equivalent of about two minutes per case.
- Two former employees specifically cited the 25-per-hour figure, framing it as a throughput target imposed by the company rather than a clinical judgment call.
- STAT is publishing the account; the LifeMD story is presented as an exclusive available to STAT+ subscribers, and the source excerpt does not include a response from LifeMD or Novo Nordisk.
Why it matters: Novo Nordisk's public endorsement of LifeMD as a "legitimate" GLP-1 provider sits in direct tension with worker testimony that its review pace was structured around prescription volume rather than clinical care — a disconnect that matters for patients routed to LifeMD through the drugmaker's own channels.
